Global Dermatological Drugs Market Size study & Forecast, by Indication (Acne, Psoriasis, Rosacea, Alopecia, Others) and Regional Analysis, 2022-2029

Global Dermatological Drugs Market Size study & Forecast, by Indication (Acne, Psoriasis, Rosacea, Alopecia, Others) and Regional Analysis, 2022-2029

Global Dermatological Drugs Market is valued at approximately USD 17.0 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 10.8% over the forecast period 2022-2029. Dermatological drugs are medical substances used to treat a variety of skin disorders and their direct concern is skin care. Various skin disorders such as Acne, Alopecia Areata, Pemphigus, and more are treated through dermatological drugs. The focus of Dermatological drugs is to cure and prevent skin disorders. Increasing skin conditions, growing awareness regarding skin diseases, increasing demand for innovative products, approval of drugs for treatment, increasing investment in research and development, and increasing disposable income are the factors driving the growth of the market.

According to Health, Pharma & MedTech, in India, around 23% of the respondents suffered from skin conditions such as acne and dandruff in 2021. According to the American Academy of Dermatology Association, around 85% of adult people aged between 12 to 24 experience minor acne. The increasing prevalence of skin conditions results in the growth of the dermatological drugs market. Additionally, the global skin treatment in 2023 was valued at around 18.71 billion, most of which is generated in the US. Increasing treatment of skin conditions shows the increasing awareness of skin diseases which drives the market growth. Other important components driving market increase are increasing demand for innovative products, approval of drugs for treatment, increasing investment in research and development, and increasing disposable income. Furthermore, an increase in healthcare expenditure and the Development of the pharmaceutical industry are the factors creating major market opportunities. However, the availability of alternatives stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Dermatological Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Europe dominated the market in terms of revenue, owing to the high number of patients with skin diseases, increasing underground hydrogen storage adoption, increasing government investment in the development of hydrogen storage capacities, rising investments in the healthcare sector, and the region's increasing investment in hydrogen energy. North America is expected to grow with the highest CAGR during the forecast period, owing to factors such as technological advancements, real-time data delivery, Increasing awareness regarding the adoption of natural gas and, supportive government regulations

Major market player included in this report are:
Novartis AG
Amgen Inc
AbbVie Inc
Johnson & Johnson Private Limited
Leo Pharma A/S
Eli Lilly and Company
GlaxoSmithKline Plc
AstraZeneca plc
Pfizer Inc
Merck KGaA
Recent Developments in the Market:
In July 2021, TWYNEO cream of Sol-Gel Technologies Ltd was approved by US FDA for the treatment of acne vulgaris.
In June 2021, Kyowa Kirin Co., Ltd. and Amgen have agreed to work together to develop and market KHK4083 for the treatment of skin diseases such as atopic dermatitis.
Global Dermatological Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Indication, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Indication offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Indication:
Acne
Psoriasis
Rosacea
Alopecia
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the WorldCompanies Mentioned
Novartis AG
Amgen Inc
AbbVie Inc
Johnson & Johnson Private Limited
Leo Pharma A/S
Eli Lilly and Company
GlaxoSmithKline Plc
AstraZeneca plc
Pfizer Inc
Merck KGaA

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.